81 FR 69544 - Prospective Grant of Exclusive Patent License: Development of a NANOG-Based Therapeutic for Cancer

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 194 (October 6, 2016)

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Summary Information section of this notice to Inova Health System located in Falls Church, VA.

[Federal Register Volume 81, Number 194 (Thursday, October 6, 2016)]
[Notices]
[Pages 69544-69545]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-24133]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive Patent License: Development of a 
NANOG-Based Therapeutic for Cancer

AGENCY: National Institutes of Health.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an exclusive patent license to practice the 
inventions embodied in the U.S. Patents and Patent Applications listed 
in the Summary Information section of this notice to Inova Health 
System located in Falls Church, VA.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before October 21, 2016 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated exclusive license should be 
directed to: Kevin W. Chang, Ph.D., Senior Licensing and Patenting 
Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 
1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, 
MD 20850-9702 Telephone: (240) 276-6910; Facsimile: (240) 276-5504 
Email: [email protected].

SUPPLEMENTARY INFORMATION: 

Intellectual Property

    United States Provisional Patent Application No. No. 61/420,214, 
filed December 6, 2010, entitled ``Allele Specific shRNAs For NANOG, 
Pharmaceutical Composition Comprising The shRNA, And Its Method of Use 
to Treat Cancer'' [HHS Reference No. E-294-2010/0-US-01]; International 
PCT Application No. PCT/US2011/063451, filed December 6, 2011, entitled 
``Pharmaceutical Composition Comprising NANOG shRNA, and Method of 
Using NANOG shRNA to Treat Cancer'' [HHS Reference No. E-294-2010/0-
PCT-02]; United States Patent No. 9,163,236, issued October 20, 2015, 
entitled ``Pharmaceutical Composition Comprising NANOG shRNA, and 
Method of Using NANOG shRNA to Treat Cancer'' [HHS Ref. No. E-294-2010/
0-US-03]; and United States Patent Application No. 14/886,970 filed 
October 19, 2015, entitled, ``Pharmaceutical Composition Comprising 
NANOG shRNA, and Method of Using NANOG shRNA to Treat Cancer'' [HHS 
Ref. No. E-294-2010/0-US-04].
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the use of Licensed Patent Rights 
for the following: ``Treatment or prevention of colorectal cancer in 
humans.''
    The subject technologies are short hair-pin RNAs which inhibit 
NANOG or NANOGP8 for the treatment of cancer and viral vectors that 
encode the RNAs. The first generation of these vectors were non-
replicating lentiviral based vectors that were introduced into cancer 
cells as a standard form of RNA inhibition, blocking the expression of 
NANOG or NANOGP8 protein. The most current version of the subject 
technology utilizes conditionally replicating, oncolytic adenovirus 
vectors. These adenovirus-based vectors grow in cells that express 
NANOGP8 but not in cells that lack NANOGP8 or where the shRNA has 
inhibited NANOGP8 expression. The vectors have been constructed to 
directly kill tumors and to inhibit the NANOGs to block cancer stem 
cell function in the tumors.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the prospective field of use 
that are filed in response to this notice will be treated as objections 
to the grant of the contemplated Exclusive Patent License Agreement. 
Comments and objections submitted to this notice will not be made 
available for public inspection and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552.


[[Page 69545]]


    Dated: September 29, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2016-24133 Filed 10-5-16; 8:45 am]
BILLING CODE 4140-01-P